BioNumerik Pharmaceuticals Observes Evidence Of A Survival Increase In Lung Cancer Patients Participating In Tavocept(TM) Clinical Trial
BioNumerik Pharmaceuticals, Inc. ("BioNumerik") announced that patients with adenocarcinoma (the most frequently occurring form of lung cancer) participating in a Phase II clinical trial of Tavocept(TM) showed a survival increase of approximately 198 days (6.5 months).
Health is the Most Precious Asset to us! Just willing to share with you what I have learned from Nutriotional Immunology.
